Literature DB >> 23124086

[A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept].

Takuma Wada1, Yuji Akiyama, Kazuhiro Yokota, Kojiro Sato, Yu Funakubo, Toshihide Mimura.   

Abstract

We report a case of rheumatoid arthritis (RA) complicated with interstitial pneumonia that deteriorated after the administration of abatacept. A 55-year-old man developed RA and interstitial pneumonia. Although interstitial pneumonia was improved by high-dose glucocorticoids, various disease-modifying antirheumatic drugs including infliximab were ineffective for his arthritis. Tacrolimus was effective but was discontinued due to refractory itching and diarrhea. After 2 months, he was registered on the Phase III trial of abatacept in Japan because of worsening of arthritis. From 2 days after the abatacept administration, frothy sputum frequently appeared, but sputum culture was negative. On 13 days after the administration, the interstitial shadow was deteriorated by chest CT as compared with that of 2 months before, and he was dropped out from the trial. On 27 days after the administration, the dose of prednisolone was increased from 2 to 10 mg/day for his arthritis. On 44 days after the administration, the interstitial pneumonia improved. Abatacpet might be the cause of the deterioration of the interstitial pneumonia, but other possibilities such as discontinuation of tacrolimus, flare-up of RA itself or viral infection should be considered. This is the first report of deteriorated interstitial pneumonia after the abatacept administration in the literature. Further cases are needed to identify the relation between abatacept and interstitial pneumonia, however this possibility should be always kept in mind when we use abatacept.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124086     DOI: 10.2177/jsci.35.433

Source DB:  PubMed          Journal:  Nihon Rinsho Meneki Gakkai Kaishi        ISSN: 0911-4300


  11 in total

1.  A case of acute respiratory failure in a rheumatoid arthritis patient after the administration of abatacept.

Authors:  Birsen Doğu; Nurhan Atilla; Gözde Yıldırım Çetin; Nezir Yılmaz; Hafize Öksüz
Journal:  Eur J Rheumatol       Date:  2016-01-29

Review 2.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 3.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 4.  Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.

Authors:  Andrea Picchianti Diamanti; Milica Markovic; Giuseppe Argento; Simonetta Giovagnoli; Alberto Ricci; Bruno Laganà; Raffaele D'Amelio
Journal:  Ther Adv Respir Dis       Date:  2016-10-12       Impact factor: 4.031

Review 5.  Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.

Authors:  James Bluett; Meghna Jani; Deborah P M Symmons
Journal:  Rheumatol Ther       Date:  2017-08-14

6.  Rapid development of severe acute respiratory distress syndrome after abatacept treatment in a patient with rheumatoid arthritis.

Authors:  Jorge Gower; Gonzalo Labarca; Daniel Enos; Estefania Nova-Lamperti
Journal:  BMJ Case Rep       Date:  2020-04-06

Review 7.  The safety of biologic therapies in RA-associated interstitial lung disease.

Authors:  Meghna Jani; Nik Hirani; Eric L Matteson; William G Dixon
Journal:  Nat Rev Rheumatol       Date:  2013-12-24       Impact factor: 20.543

Review 8.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08

Review 9.  Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.

Authors:  Giulia Cassone; Andreina Manfredi; Caterina Vacchi; Fabrizio Luppi; Francesca Coppi; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

10.  IL-17A+GM-CSF+ Neutrophils Are the Major Infiltrating Cells in Interstitial Lung Disease in an Autoimmune Arthritis Model.

Authors:  Oh Chan Kwon; Eun-Ju Lee; Eun-Ju Chang; Jeehee Youn; Byeongzu Ghang; Seokchan Hong; Chang-Keun Lee; Bin Yoo; Yong-Gil Kim
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.